Efficacy Study of Telbivudine in Chronic Hepatitis B Patients

NCT01958229 · clinicaltrials.gov ↗

COMPLETED

Status

23

Enrollment

OTHER

Sponsor class

Conditions

Chronic Hepatitis B
Roadmap Concept in Chronic Hepatitis B Treatment
24-week PCR Negativity of Telbivudine
PCR Negativity at 52 and 104 Week
HBeAg Seroconversion Rate at 52 and 104 Week

Sponsor

National Taiwan University Hospital